Kaiser Permanente Washington Health Research Institute Doses First Patient for COVID-19 Vaccine with Moderna’s mRNA-1273

Kaiser Permanente Washington Health Research Institute Doses First Patient for COVID-19 Vaccine with Moderna’s mRNA-1273

A Phase I clinical trial evaluating Moderna’s mRNA-1273 to fight against COVID-19 commenced at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle—the clinical investigational site was able to dose the first patient. The National Institute of...
NIAID Recent Advances in Addressing TB

NIAID Recent Advances in Addressing TB

A new “Perspective” in the Journal of Infectious Diseases by NIAID Director Anthony S. Fauci, MD, and other institute officials summarizes recent progress in improved TB diagnostics, therapeutic regimens and prevention approaches that made 2019 a “banner year” for TB...

Pin It on Pinterest